Staging criteria for heart failure (HF) range from stage 0 (without risk) to being at risk (stage A) to presence of cardiac structural/ functional abnormalities (stage B) to symptomatic/end stage (stages C/D). There are limited data on the prevalence of these stages in early adulthood and predictors of HF stage and symptoms in middle age.
P revalence of heart failure (HF) is increasing in the United States, particularly in blacks and those >60 years of age. 1 The American Heart Association/American College of Cardiology has established staging criteria for HF ranging from not being at risk (stage 0) to being at risk (stage A) to presence of cardiac structural or functional abnormalities (stage B) to symptomatic HF (stages C and D). 2 The presymptomatic stages (A and B) predict incident HF in middle-aged and older individuals. [3] [4] [5] HF may be the first manifestation of acquired cardiovascular disease, particularly in blacks. 6 There is limited information on the antecedents of these stages and on prevalence in blacks, especially before middle age. The CARDIA study (Coronary Artery Risk Development in Young Adults) has collected both phenotypic and echocardiographic data at 22 to 37 years (exam year 5) and at 47 to 62 years of age (exam year 30) in white and black men and women to allow assessment of the antecedents and progression of HF stages.
The objectives of this article are to (1) estimate the prevalence of HF stages by race and sex in the CAR-DIA cohort at the year 5 examination when participants were 22 to 37 years of age to assess evolution of HF stages over time, (2) determine the prevalence of HF stages by race and sex in the CARDIA cohort at the year 30 examination when participants were 47 to 62 years of age, and (3) compare characteristics of the cohort (year 5) by HF stage at year 30. We hypothesized that the prevalence of more advanced HF stages would increase over time, blacks would be more adversely affected, and obesity would be associated with prevalence of later stages of HF.
METHODS
CARDIA is a longitudinal epidemiological study initiated in 1985 to 1986 with a primary goal of understanding the evolution of cardiovascular risk factors beginning in young adulthood using a population-based healthy cohort stratified by sex, race (black/white), and education (above and below a high school education). 7 Examinations have been conducted at years 0, 2, 5, 7, 10, and every 5 years thereafter at 4 field centers located in Chicago IL, Birmingham AL, Oakland CA, and Minneapolis MN. Research protocols have been approved by local institutional review boards, and informed consent has been obtained from all participants at each examination. A single coordinating center at the University of Alabama, Birmingham, has supervised data collection. Data for this article were primarily obtained from the year 5 and year 30 examinations, when echocardiograms were obtained. 7, 8 Information on gaining access to CARDIA data can be found at the CARDIA website. 9 HF stages were defined according to the 2013 American Heart Association/American College of Cardiology guidelines that classified HF into progressive stages: stage 0, without risk; stage A, HF risk factors; stage B, asymptomatic cardiac structural or functional abnormalities; stage C, symptomatic; or stage D, end-stage HF ( Table 1 ). 2 In this analysis, stages C and D were combined because of small sample size. Criteria for defining components of stages A through D follow. Hypertension was defined as systolic blood pressure (BP) ≥140 mm Hg, or diastolic BP ≥90 mm Hg, or taking antihypertensive medication to be consistent with the original staging classification. Diabetes mellitus was defined as either fasting blood glucose ≥126 mg/dL or taking diabetic medication. Obesity was defined as body mass index ≥30 kg/m 2 . Metabolic syndrome was defined according to the National Cholesterol Education Program Adult Treatment Panel III as the presence of ≥3 of the following components: waist circumference >102 cm in men and >88 cm in women, triglycerides ≥150 mg/dL, HDL (high-density lipoprotein) cholesterol <40 mg/dL in men and <50 mg/dL in women, BP ≥130/85 mm Hg or taking BP medication, and fasting glucose ≥100 mg/dL. 10 Atherosclerotic disease included in addition to adjudicated coronary heart disease (for stage B classification), carotid artery disease, nonmyocardial infarction acute coronary syndrome, and peripheral artery disease. End-stage renal disease was defined as requiring chronic dialysis therapy. 9 Cardiac structural or functional abnormalities included significant valvular disease (moderate or greater aortic or mitral stenosis, aortic or mitral regurgitation); the presence of reduced left ventricular (LV) ejection fraction was defined as <40%; LV hypertrophy was defined as LV mass indexed to body surface area >95 g/m 2 for women and >115 g/m 2 for men (American Society of Echocardiography definitions of LV hypertrophy and reduced ejection fraction). 11, 12 Prevalent HF was based on adjudicated HF events. Criteria requiring a medical diagnosis (eg, prior myocardial infarction, cancer, HIV, HF symptoms/diagnosis) were ascertained by CARDIA investigators' review of relevant hospital records and laboratory studies. 6, 9 Information not available in the CARDIA data set was primarily information related to family history of cardiomyopathy. Stage 0 was determined by failure to satisfy any of the above criteria among those with sufficient nonmissing information to make that judgment.
WHAT IS NEW?
• Onset of heart failure by middle age is strongly associated with American Heart Association/American College of Cardiology risk stage at 23 to 35 years of age. • Risk for heart failure increases dramatically between 23 and 35 years of age and 48 to 60 years of age. • Blacks are disproportionately affected. • Tobacco use and low self-reported physical activity may also be associated with progression of heart failure stage.
WHAT ARE THE CLINICAL IMPLICATIONS?
• Prevention of heart failure will require improved control of risk factors, particularly obesity and hypertension, at a young age. • Blacks should receive particular attention.
The cohort was assembled from those participating in the CARDIA year 5 examination. The method of cohort selection is provided in Figure 1 . Descriptive statistics were calculated. The cohort used for the primary analyses was examined and had complete data for both time points. Descriptive statistics were calculated. Comparisons across groups were made by χ 2 or t test as appropriate. Sensitivity analyses used data from the entire examined cohorts at years 5 and 30. These included recalculation of HF stage prevalence at year 30 after inverse probability weighting to address potential bias due to loss-to follow-up. Total cardiac and HF deaths were related to year 5 stage in the sensitivity analysis. Comparisons of the subgroup with stage B HF risk at year 5 for various associated traits including self-reported 
RESULTS
For the primary analysis, 2189 CARDIA participants with complete data allowing classification of HF stage at both years 5 and 30 were included. The prevalence of each stage for the cohort as a whole, by age, and by race and sex at years 5 and 30 is presented in Figures 2  through 4 . At year 5, just above 20% of the cohort was at risk for HF being in stage A or B with 13% of whites, 24% of black men, and 35% of black women at risk. At year 30, over two-thirds of the cohort was at risk for HF (stage A or B), whereas 1% had symptomatic HF. Prevalence of each stage was relatively constant within the CARDIA 13-year age range. Blacks were far more likely to be at risk for HF (stage A or B) or have symptomatic HF than whites. Only about 20% of blacks were in stage 0 at year 30, whereas white women were most likely to be in stage 0.
Average risk factor levels in year 5 by HF stage in year 30 are presented in Table 2 . Risk factor levels increase with each stage by definition, particularly hypertension, obesity, and diabetes mellitus. Risk factors more common in those with symptomatic HF 25 years later were obesity, LV hypertrophy, and decreased self-reported physical activity.
Risk factors at year 30 by HF stage are also reported in Table 2 . About three-quarters of those in stage A and stage C/D were obese, and 44% of those in stage B were obese. Those at risk for HF at year 30 had lower self-reported physical activity than those not at risk, and average fasting glucose was >100 mg/dL. Lower educational attainment was associated with HF and change in stage. Of those in stage C/D, 80% were black. All cardiovascular risk factors except for lipids had high prevalence. Interestingly, lipids declined substantially in those with symptomatic HF at year 30 compared with values at year 5. Table I in the Data Supplement shows risk factor data by HF stage at year 30 by race and sex. Whites were more likely to be in stage 0, and there were only 4 white participants in stage C/D. Although quantitatively different by race and sex, the trends reported above remained similar across all 4 groups. Table 3 presents a cross-tabulation of HF stage at year 5 with HF stage at year 30 by ethnicity. For the entire cohort, 62% of those in stage 0 at baseline progressed to stage A, B, or symptomatic HF. Blacks were more likely to be in any stage or with morbidity at both time points because of higher risk factor prevalence. At year 5 for stage A (at risk), only 6 of 345 (1.7%) changed status at year 30. Blacks were much more likely to move to an advanced HF stage. The presence of stage A or B at year 5 was significantly associated with incident symptomatic HF with 13 of 20 incident events occurring in the 21% of the cohort in stage A or B at year 5. This trend was particularly true for blacks, whereas for whites, all incident stage C HF occurred in those in stage 0 at year 5.
Interestingly, many participants in stage B changed to stage A or stage 0 (typically by improvement in LV mass or ejection fraction). Changes in LV mass or ejection fraction in those whose status improved to stage 0 often reflected small changes in those variables (within 10% of the baseline value). By definition, this group did not have risk factors associated with stage A (Table 4 ). Secondary analyses looking at self-reported physical activity and endurance on treadmill testing at other CARDIA examinations were not different in those who went from stage B to stage 0.
Sensitivity analyses performed with the excluded cohort showed the excluded sample had more men, more blacks, and worse risk status for all risk factors except lipids (Table II in the Data Supplement). The excluded cohort had higher LV mass at year 5 and was more likely to have low ejection fraction (P<0.001). Weighted probability analysis results were similar to those reported above and suggested results reported above are slight underestimates based on the higher prevalence of risk in the excluded cohort ( Table III in (75.2%) were stage 0, 640 (18.6%) were stage A, and 214 (6.2%) were stage B. Percentage all-cause cardiac mortality by stage was 11 of 2594 (0.4%), 12 of 640 (1.9%), and 5 of 214 (2.3%), and HF mortality was 7 of 2594 (0.3%), 4 of 640 (0.6%), and 1 of 214 (0.5%). These numbers were too small for statistical analysis but showed a trend relating increased likelihood of cardiac death to HF stage at year 5.
DISCUSSION
In the racially diverse CARDIA cohort followed for 25 years with careful cardiovascular phenotyping, by ages 47 to 62 years, the majority of participants were at risk for HF. Blacks have a higher prevalence of risk than whites. Similarly, blacks have a higher prevalence of symptomatic HF. These results are consistent with analyses among middle-aged, community-dwelling individuals in Olmsted County, the Framingham Heart Study, and Atherosclerosis Risk in Communites study. [3] [4] [5] In 1990, at ages 22 to 37, the prevalence of HF stages A and B was much lower in this cohort. However, about two-thirds of future HF cases and deaths come from those in stage A or stage B, about 20% to 25% of the year 5 cohort. A trend toward total cardiac mortality during the 25-year follow-up also was related to HF stage at year 5. Prior CARDIA analyses have shown the higher likelihood of blacks to develop HF in young adulthood/early middle age and the importance of cardiac structural measures in predicting future cardiovascular events. 6, 13, 14 Estimates in this study are likely lower than actual prevalence in the general population as shown by our weighted probability sensitivity analysis, based on risk present in the cohort not evaluable at year 30. Beyond the criteria provided in the American Heart Association/American College of Cardiology classification system, these data emphasize the importance of tobacco use, relatively low self-reported physical activity, and black race to identify individuals who may be at risk in young adulthood and early middle age because these characteristics were associated with HF risk in year 5 and symptomatic HF/deaths at year 30.
Three cohort studies have looked at the prevalence of HF stages. In the Framingham Heart Study, with a cohort of average age of 51 years similar to this study, Xanthakis et al 4 showed a prevalence of stage A of 36.5% and stage B of 24.2% with increasing prevalence with increasing age. Biomarkers related to HF were associated with stages A and B. Methodology was similar to this study. In Olmsted County, Minnesota, a cohort of individuals with median age >60 years (age range, 45 to >75 years) had a prevalence of stage A of 22%, stage B of 34%, and stages C and D of 12%. 5 Five-year survival and brain natriuretic peptide levels were directly related to HF stage. Determination of cardiac structural abnormalities included electrocardiographic criteria for LV hypertrophy, a qualitative definition of diastolic dysfunction, and different criteria for assessing LV cavity size than in this study. These cohorts are predominantly white. In the ARIC study of blacks and whites with a median age of 75 years (range, 66-90 years), Shah et al 3 showed that only 5% of the cohort was without HF risk. Stage A prevalence was 52%, stage B was 30%, and 13% had symptomatic HF. Longitudinal analyses showed that both echocardiographic criteria included in the stage B classification and newer measures such as speckle tracking echocardiography improved the ability to risk stratify. ARIC used study-specific criteria for cardiac structure and function abnormalities because of the older age of the cohort. In a separate ARIC analysis, physical activity and change in physical activity have been associated with incident HF. 15 The Jackson Heart Study showed cigarette smoking was associated with incident HF. 16 We have shown in the CARDIA study that LV mass has a modest effect on cardiovascular risk reclassification based on the Framingham Heart Study risk equation. 13 Observations from long-term observational studies have consistently linked risk exposures in adolescence and young adulthood to subclinical cardiovascular outcomes decades later in young adulthood and middle age. A consistent finding across CARDIA analyses is that risk identified in young adulthood predicts subclinical outcomes such as LV hypertrophy, adverse LV structure, adverse changes in cardiac function, and the presence of coronary artery calcium 15 to 25 years hence. [17] [18] [19] [20] In this cohort and the MESA (Multi-Ethnic Study of Atherosclerosis) cohort, Liu et al 21 have shown that treatment of elevated BP to lower levels does not restore subclinical disease burden or incident clinical disease risk to the same level as individuals whose BP was always at the lower level. This failure may be, in part, related to chronic exposure before initiation of treatment. Several cohorts with participants followed from adolescence and with subclinical cardiovascular measures in young adulthood show strong relationships of adolescent risk to adult subclinical cardiac structure and function, as well as carotid intima-media thickness. [22] [23] [24] These analyses suggest 2 opportunities to lower the prevalence of HF stages A through D, later in life. The first is obesity prevention or treatment. The presence of obesity and obesity-related comorbidities, diabetes mellitus and hypertension, drive the high prevalence of stage A and contribute to stage B classification, cardiac structural abnormalities, and prevalent atherosclerosis in the CARDIA cohort. 17, 25 The second is earlier recognition of treatable risk factors, particularly hypertension and smoking. 26, 27 Several studies have shown that treatment of hypertension lowers risk of incident HF. In this study, essentially no one improved from stage A to stage 0 status over 25 years of fol-low-up. 26 Observational studies support adherence to healthy lifestyle and risk factor control are associated with lower future event rates in men, women and across ethnicities. [28] [29] [30] Cardiovascular disease mortality rates in middle-aged adults are not declining, particularly in women. 31 Part of this failure to impact cardiovascular disease mortality rates appears attributable to the obesity epidemic. 31 The CARDIA cohort was recruited around the onset of the obesity epidemic; secular trends in the prevalence of obesity likely contribute to the development of increased HF risk during follow-up. 32 A second cause may be the absence of an evidence base for treatment in vulnerable 20 to 50 year olds. The absence of clinical trial data contributes to low evidence grades regarding efficacy of true preventive therapy for high-risk individuals and low awareness among clinicians of the need for early management of risk factors. Trials powered to have events as end points require high-risk populations with events likely to occur within 5 years of trial initiation; otherwise, the cost of conducting the trials would be prohibitive. This creates a bias against recognition of younger individuals with lower short-term risk but high lifetime risk. For example, currently only 28% of adults <50 years of age who meet entry criteria for the systolic blood pressure intervention trial currently receive antihypertensive medication according to national health and nutrition examination survey data. 27 Data from CARDIA and other longitudinal studies suggest that high-risk, younger adults can be identified for clinical trials. Valid end points for these studies might be both events and improvement in structural and functional cardiac abnormalities. Although a high percentage of those with stage B classification at year 5 went on to develop HF or died related to HF, about one-third of those in stage B improved to stage 0 over 25 years. The typical profile of the person who changed status was the absence of cardiovascular risk factors, particularly obesity, at year 5 and year 30 but a change secondary to either LV mass or LV ejection fraction being within 10% of the thresholds for classification. This change is consistent with the measurement error observed from quality control analyses at the echocardiography reading center. 8 Thus, caution should be used in the clinical setting in overinterpreting borderline values for ejection fraction or LV mass in the absence of other HF risk factors.
An important limitation of this study is the lack of data on those CARDIA participants not examined at year 30. Follow-up with over 90% of the cohort is achieved every 6 months by telephone, even those not attending examinations. Important medical events occurring in the interval may be missed. Event ascertainment may be incomplete, and the interval between echocardiograms was 25 years. Our sensitivity analysis reviewing risk status of the excluded cohort suggested actual HF events in the full cohort occurred at slightly higher frequency than the cohort examined in detail. Prevalence estimates may be different for other race/ ethnic groups than blacks and whites.
In summary, we have confirmed that many middleaged US blacks and whites are at risk for HF, with blacks at the highest risk. Prevalence of HF stages increases dramatically from young adulthood in this cohort of participants born in 1954 to 1967, when about 13% of whites and 30% of blacks are at risk. The majority of incident HF events occur in those in HF stage A or B at a young age with those in stage 0 being at low risk. Tobacco use and low self-reported physical activity may add information to the current staging system. Opportunities for prevention abound.
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